ELZONRIS – Cost

Elzonris’ HCPCS Code, J9269, became effective in October of 2019. Since it’s HCPCS became effective, Elzonris has taken several minor changes to its list price. The ASP for Elzonris has steadily risen, lagging two quarters behind its WAC price increases.

DEMEROL – Cost

Demerol is a generic drug aligned to the HCPCS code J2175, which has been effective since the first quarter of 1997. Observing Demerol between 2016-2024, the pricing for certain NDCs aligned to J2150 have taken increases, while others have remained at the same price. Demerol’s average sales price has remained relatively stable across this same time period, increasing by roughly 50% over eight years.

CYSVIEW – Cost

Cysview’s HCPCS code, A9589, was added and has been effective since January 1, 2019. Since January 2019, the AWP has undergone slight, incremental increases about once per year. The WAC has followed a similar pattern, with incremental increases around the same times. The ASP has indergone some slight fluctuations, rising and falling in very minor amounts, but has overall risen very slightly since the drug’s debut.

CINQAIR – Cost

Cinquair is aligned to the HCPCS Code J2786, which became effective in January 2017. Cinquair has implemented list price changes every six to twelve months since it became effective. Cinquair’s ASP was first published in the fourth quarter of 2018 within 2-3% of its WAC list price. Cinquair’s average sales price has remained close to its WAC through early 2024.

CEREZYME – Cost

Cerezyme is aligned to the J Code J1786 which was added and became effective on January 1st, 2011. Cerezyme took several annual list price increases between May 2018 and February 2022. It’s list price has remained steady between February 2022 and January 2024. Cerezyme’s ASP has closely trailed its WAC list price, remaining within a roughly 5% margin.

BIVIGAM – Cost

Bivigam’s HCPCS Code, J1556, was added and became effective on January 1st, 2014. The WAC and AWP have remained relatively stable since, occasionally taking adjustments. Bivigam’s ASP rose dramatically in January of 2018 nearly doubling in value. Since then, Bivigam’s average sales price has remained relatively stable.

VENOFER – Cost

Venofer HCPCS Code (J1756) became effective in January 2003. Looking back to 2016, Venofer’s list price has remained stable and it’s ASP has slowly decreased. Currently, both American Regent and Fresenius Kabi have NDC codes aligned to Venofer (J1756).

EOVIST – Cost

Eovist has a HCPCS code of A9581. This HCPCS code was added and became effective January 1, 2010. Between January 2016 and August 2017, the WAC and the AWP remained consistent, and both had a sharp increase in September 2017. From September 2017 to February 2024, both the WAC and the AWP have remained at the same level. Between January 2016 and March 2018, the ASP underwent some slight fluctuations. The ASP underwent a sharp increase in April 2018, but since then has remained fairly consistent with very slight fluctuations.

TYSABRI – Cost

Tysabri is aligned to the HCPCS code J2323, which became effective in the first quarter of 2008. Between 2016 and 2024, Tysabri has taken minor list price increases every 6 to 12 months. Tyrabri’s ASP has remained relatively close to its WAC price during this time period, indicating a moderate degree of discounting by Biogen.

TIVDAK – Cost

Tivdak’s J Code, J9273, became effective on April 1st, 2022. Tivdak has taken incremental list price increases every six months. Between Tivdak’s effective date and January 2024, these list price increases have occurred in October and April. Tivdak’s ASP was first published three months after its effective date, in July 2022. Since then, Tivdak’s ASP has closely trailed its WAC indicating a lack of significant discounting.